JCJeffery M. Cleland

Jeffery M. Cleland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffery M. Cleland has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recombinant Xeno-Free Vitronectin Supports Self-Renewal and Pluripotency in Protein-Induced Pluripotent Stem Cells

    by Ramesh R. Kaini, Jane Shen-Gunther, Jeffery M. Cleland, Whitney A. Greene, Heuy-Ching Wang

    Patient safety is a major concern in the application of induced pluripotent stem cells (iPSCs) in cell based therapy. Efforts are being made to reprogram, maintain, and differentiate iPSCs in defined conditions in order to provide a safe source of stem cells for regenerative medicine. Recently, human fibroblasts were successfully reprogrammed into pluripotent stem cells (PSCs) using four recombinant proteins (OCT4, c-Myc, KLF4, & SOX2) fused with a cell-penetrating peptide (9R). These protein-induced pluripotent stem cells (piPSCs) are maintained and propagated on a feeder layer of mouse embryonic fibroblasts (MEF). Use of animal-derived products in maintenance and differentiation of iPSCs poses risks of zoonotic disease transmission and immune rejection when transplanted into humans. To avoid potential incorporation of xenogenic products, we cultured piPSCs on recombinant human matrix proteins. We then tested whether recombinant human matrix proteins can support self-renewal and pluripotency of piPSCs. After long term culture on recombinant human vitronectin in xeno-free conditions, piPSCs retained the expression of pluripotent markers. The pluripotency of these cells was further evaluated by differentiating towards ectoderm, mesoderm, and endoderm lineages in vitro. In conclusion, recombinant human vitronectin can support the long-term culture, and maintain the stemness of piPSCs in defined, non-xenogenic conditions.